Setting Specifications for a Biotech Therapeutic Product in the Quality by Design Paradigm - Manufacturing using meaningful, science-based specifications will ensure that we attain the optimal balance

ADVERTISEMENT

Setting Specifications for a Biotech Therapeutic Product in the Quality by Design Paradigm
Manufacturing using meaningful, science-based specifications will ensure that we attain the optimal balance between manufacturing flexibility and product safety.


BioPharm International
Volume 23, Issue 1

SETTING SPECIFICATIONS

Developing and setting specifications in the QbD paradigm should be a data-based exercise that allows for incorporating data as it becomes available during the product lifecycle. Each specification has three key elements:7,8

  • a quality attribute or parameter that the specification is targeting
  • an analytical method that is used to perform the test
  • quantitative or qualitative acceptance criteria that determine acceptance or rejection of a manufacturing lot.


Figure 1. Illustration of an approach for setting specifications for product quality attributes
The first step is to perform a risk assessment to determine which quality attributes are important to the clinical performance of the product (safety and efficacy).7 All product quality attributes are considered and assessed for risk; this approach is illustrated in Figure 1. Data available on the product or from other platform products are analyzed.

After attributes have been identified for specifications, the next step is to come up with justifiable acceptable criteria.7,8,13,16,17 As discussed above, setting product specifications requires sifting through a variety of analyzing data from sources (clinical studies, animal models, pharmacokinetic studies, analysis of manufacturing lots, etc.) This necessitates the use of appropriate statistical tools. Multivariate techniques are more effective than univariate methods for the two-step process of first treating the raw data and then combining data sets to produce meaningful results.17

Here are some key considerations that should be kept in mind when setting specifications:2,5,6,16

  • Some raw materials such as cell banks may require specifications to ensure that no contaminants are introduced into the product. Excipients added to the final drug product are expected to meet pharmacopoeial specifications.
  • A subset of in-process controls may have specifications associated with them to ensure the absence of contamination or removal of an impurity.
  • Validation studies may demonstrate that some process-related impurities such as DNA and HCPs do not require specifications.
  • Drug substance and drug product specifications are designed to measure the identity, purity, and potency of the product.
  • Control limits may be set based on process and analytical method variability (such as 3 standard deviation). These limits can be useful for identifying any trends, thus triggering an investigation to find the root cause before lot failure is observed.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Pfizer to Acquire Vaccines from Baxter
July 30, 2014
GSK Submits EU Regulatory Filing for Malaria Vaccine Candidate
July 29, 2014
Bristol-Myers Squibb and Ono Pharmaceutical Collaborate on Immunotherapies
July 28, 2014
FDA Accepts First Biosimilar Filing
July 24, 2014
Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
Author Guidelines
Source: BioPharm International,
Click here